Business Context and Reporting Period
Company: Lifecore Biomedical, Inc. (LFCR)
Filing Type: Form 8-K (Current Report)
Date of Report: February 13, 2024 (Event Date)
Reporting Period: The filing addresses the Company's failure to file periodic reports for the fiscal year ended May 28, 2023, and the quarterly periods ended August 27, 2023, and November 29, 2023.
Key Financial Metrics
This filing is a notice of delisting proceedings and does not contain updated financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. The filing text does not provide a clear value for any current financial performance indicators.
Material Changes and Delisting Notice
- Delisting Determination: On February 13, 2024, Nasdaq issued a Staff Delisting Determination due to the Company's non-compliance with Listing Rule 5250(c)(1), which requires timely filing of periodic financial reports.
- Delinquent Filings: The Company has not filed its Annual Report on Form 10-K for the fiscal year ended May 28, 2023, nor its Quarterly Reports on Form 10-Q for the periods ended August 27, 2023, and November 29, 2023.
- Extension Deadline: Nasdaq had granted an 180-day extension to regain compliance, which expired on February 12, 2024. The Company failed to file the required reports by this deadline.
- Reason for Delay: The delay is attributed to the Company working with auditors to complete a previously disclosed restatement of consolidated financial statements for fiscal years ended May 29, 2022, and May 30, 2021, as well as various unaudited quarterly periods.
Outlook, Management Commentary, and Risks
- Appeal Process: The Company intends to appeal the Staff Determination before a Nasdaq Hearing Panel. A request for a hearing must be filed by 4:00 p.m. Eastern Time on February 20, 2024.
- Stay of Delisting: Filing a hearing request will automatically stay the suspension of securities for 15 days. The Company also intends to request a further stay pending the hearing process.
- Timeline: Hearings are typically scheduled 30-45 days after the request. The Company may further appeal the Hearing Panel's decision to the Nasdaq Listing Council.
- Risks: There is no assurance that the delinquent reports will be filed before a hearing occurs or that the Hearing Panel will grant a stay. If the appeal fails and reports remain unfiled, the Company's securities could be delisted from the NASDAQ Global Select Market.
Investor Verification Checklist
- Verify the status of the Company's appeal request with the Nasdaq Hearing Panel (deadline: February 20, 2024).
- Monitor for the filing of the delinquent Form 10-K and Form 10-Q reports to determine if compliance is regained.
- Review the details of the financial restatement for fiscal years 2021 and 2022 to understand the magnitude of the accounting issues.
- Check for any subsequent press releases or 8-K filings regarding the outcome of the Nasdaq hearing or further delisting actions.